Free Trial
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free ABUS Stock Alerts

Arbutus Biopharma (ABUS) Financials

Arbutus Biopharma logo
$4.24 -0.11 (-2.53%)
Closing price 04:00 PM Eastern
Extended Trading
$4.24 0.00 (0.00%)
As of 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Arbutus Biopharma

Annual Income Statements for Arbutus Biopharma

This table shows Arbutus Biopharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -63 -384 -85 -67 -165 -76 -88 -69 -73 -70 -34
Consolidated Net Income / (Loss)		 -63 -384 -84 -57 -154 -64 -76 -69 -73 -70 -34
Net Income / (Loss) Continuing Operations		 -63 -384 -84 -96 -154 -64 -76 -69 -73 -70 -34
Total Pre-Tax Income 		-79 -489 -109 -61 -166 -64 -76 -65 -73 -70 -34
Total Operating Income		 -104 -492 -111 -90 -144 -58 -74 -65 -78 -76 -38
Total Gross Profit		 23 1.49 11 5.95 6.01 6.91 11 39 18 6.17 14
Total Revenue		 23 1.49 11 5.95 6.01 6.91 11 39 18 6.17 14
Operating Revenue		 23 1.49 11 5.95 6.01 6.91 11 39 18 6.17 14
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 127 493 122 96 150 65 85 104 96 82 52
Selling, General & Admin Expense		 26 39 16 16 18 15 17 18 22 22 16
Research & Development Expense		 52 61 63 58 58 49 66 84 74 54 25
Restructuring Charge		 9.66 0.00 0.00 4.80 0.16 0.06 - - 0.00 3.72 13
Other Special Charges / (Income)		 - - - 0.00 6.09 0.47 1.87 2.23 0.07 2.63 -1.83
Total Other Income / (Expense), net		 25 2.47 2.20 -10 -22 -5.94 -2.73 0.44 5.25 6.40 4.66
Interest Expense		 0.00 0.00 0.26 0.23 2.11 4.01 2.86 1.73 0.46 0.14 0.10
Interest & Investment Income		 0.67 1.39 1.54 3.05 -20 -1.80 0.13 2.19 5.69 6.59 4.07
Other Income / (Expense), net		 24 1.08 0.92 26 0.04 -0.12 0.01 -0.02 0.03 -0.05 0.69
Basic Earnings per Share		 ($1.38) ($7.24) ($1.56) ($1.21) ($2.89) ($1.00) ($0.83) ($0.46) ($0.44) ($0.38) ($0.17)
Weighted Average Basic Shares Outstanding		 45.46M 53.07M 54.72M 55.30M 57.09M 75.84M 106.24M 150.94M 165.96M 185.61M 191.60M
Diluted Earnings per Share		 ($1.38) ($7.24) ($1.56) ($1.21) ($2.89) ($1.00) ($0.83) ($0.46) ($0.44) ($0.38) ($0.17)
Weighted Average Diluted Shares Outstanding		 45.46M 53.07M 54.72M 55.30M 57.09M 75.84M 106.24M 150.94M 165.96M 185.61M 191.60M
Weighted Average Basic & Diluted Shares Outstanding		 45.60M 55.02M 55.07M 55.30M 57.09M 75.84M 148.64M 162.57M 179.49M 191.48M 195.48M

Quarterly Income Statements for Arbutus Biopharma

This table shows Arbutus Biopharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -20 -19 -18 -20 -20 -13 -25 2.52 -7.74 -3.76 170
Consolidated Net Income / (Loss)		 -20 -19 -18 -20 -20 -13 -25 2.52 -7.74 -3.76 170
Net Income / (Loss) Continuing Operations		 -20 -19 -18 -20 -20 -13 -25 2.52 -7.74 -3.76 170
Total Pre-Tax Income 		-20 -19 -18 -20 -20 -13 -25 2.52 -7.74 -3.76 170
Total Operating Income		 -22 -21 -19 -22 -21 -14 -26 1.49 -8.66 -5.29 169
Total Gross Profit		 4.66 2.15 1.53 1.73 1.34 1.57 1.76 11 0.53 1.05 179
Total Revenue		 4.66 2.15 1.53 1.73 1.34 1.57 1.76 11 0.53 1.05 179
Operating Revenue		 4.66 2.15 1.53 1.73 1.34 1.57 1.76 11 0.53 1.05 179
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 26 22 21 23 23 16 27 9.25 9.19 6.34 10
Selling, General & Admin Expense		 5.84 5.10 5.31 7.55 4.54 4.71 5.83 3.33 3.04 3.69 5.89
Research & Development Expense		 20 18 15 16 14 8.81 8.96 5.50 5.78 5.01 4.12
Other Operating Expenses / (Income)		 0.21 - 0.18 0.21 0.34 - 0.30 0.26 0.27 - 0.21
Restructuring Charge		 0.00 - 0.00 0.00 3.63 - 12 0.17 0.10 0.30 0.00
Total Other Income / (Expense), net		 1.45 0.80 1.49 1.79 1.72 1.40 1.17 1.04 0.92 1.53 0.79
Interest Expense		 0.05 0.04 0.04 0.03 0.03 0.03 0.03 0.03 0.02 0.02 0.02
Interest & Investment Income		 1.49 1.47 1.55 1.83 1.75 1.46 1.20 1.04 0.95 0.88 0.82
Other Income / (Expense), net		 0.01 -0.62 -0.01 -0.01 0.01 -0.03 0.00 0.02 -0.01 0.68 -0.01
Other Gains / (Losses), net		 - - - - - - - - - - 0.79
Basic Earnings per Share		 ($0.12) ($0.12) ($0.10) ($0.11) ($0.10) ($0.07) ($0.13) $0.01 ($0.04) ($0.01) $0.88
Weighted Average Basic Shares Outstanding		 167.51M 165.96M 175.63M 188.04M 189.00M 185.61M 190.71M 191.55M 191.78M 191.60M 193.77M
Diluted Earnings per Share		 ($0.12) ($0.12) ($0.10) ($0.11) ($0.10) ($0.07) ($0.13) $0.01 ($0.04) ($0.01) $0.87
Weighted Average Diluted Shares Outstanding		 167.51M 165.96M 175.63M 188.04M 189.00M 185.61M 190.71M 192.40M 191.78M 191.60M 195.21M
Weighted Average Basic & Diluted Shares Outstanding		 167.70M 179.49M 188.72M 188.78M 189.49M 191.48M 191.53M 191.70M 192.32M 195.48M 197.54M

Annual Cash Flow Statements for Arbutus Biopharma

This table details how cash moves in and out of Arbutus Biopharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 95 -143 31 -17 -5.21 20 57 -79 -4.49 10 -18
Net Cash From Operating Activities		 -56 -58 -49 -68 -71 -51 -68 -35 -86 -65 -40
Net Cash From Continuing Operating Activities		 -56 -58 -49 -29 -71 -51 -68 -35 -86 -65 -40
Net Income / (Loss) Continuing Operations		 -63 -384 -84 -57 -154 -64 -76 -69 -73 -70 -34
Consolidated Net Income / (Loss)		 -63 -384 -84 -57 -154 -64 -76 -69 -73 -70 -34
Depreciation Expense		 0.59 1.09 2.03 2.18 2.03 1.98 1.75 1.43 1.40 1.38 0.36
Amortization Expense		 - - - 0.00 0.28 0.21 1.00 -0.05 -2.20 -3.14 -2.35
Non-Cash Adjustments To Reconcile Net Income		 36 429 54 3.00 99 9.21 3.17 1.25 5.87 7.03 7.70
Changes in Operating Assets and Liabilities, net		 -30 -104 -20 -16 -19 0.90 2.80 31 -18 -0.20 -12
Net Cash From Investing Activities		 7.68 -99 28 -4.13 28 -15 -13 -75 51 23 16
Net Cash From Continuing Investing Activities		 7.68 -99 28 -4.13 28 -15 -13 -75 51 23 16
Purchase of Property, Plant & Equipment		 -2.29 -4.00 -7.26 -1.14 -0.59 -0.23 -0.81 -0.51 -1.01 -0.18 0.00
Purchase of Investments		 0.00 -95 - -122 -59 -86 -82 -130 -81 -142 -140
Sale of Property, Plant & Equipment		 0.00 0.03 0.00 0.03 0.01 - - 0.00 0.02 0.00 0.36
Sale and/or Maturity of Investments		 9.65 - 35 119 88 73 70 56 132 165 155
Net Cash From Financing Activities		 144 13 49 56 37 87 137 32 31 52 5.72
Net Cash From Continuing Financing Activities		 144 13 49 56 37 87 137 32 31 52 5.72
Issuance of Common Equity		 142 0.00 - 0.00 19 86 135 21 30 45 0.18
Other Financing Activities, net		 1.69 0.64 0.45 1.38 19 0.45 2.11 0.12 0.26 7.48 5.54
Effect of Exchange Rate Changes		 -0.58 1.00 2.37 -1.00 - 0.06 0.01 -0.02 0.03 -0.05 0.01

Quarterly Cash Flow Statements for Arbutus Biopharma

This table details how cash moves in and out of Arbutus Biopharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -9.67 8.75 17 20 -31 4.48 0.75 0.34 -15 -4.40 5.70
Net Cash From Operating Activities		 -22 -17 -19 -15 -21 -10 -13 -16 -5.82 -4.68 -8.11
Net Cash From Continuing Operating Activities		 -22 -17 -19 -15 -21 -10 -13 -16 -5.82 -4.68 -8.11
Net Income / (Loss) Continuing Operations		 -20 -19 -18 -20 -20 -13 -25 2.52 -7.74 -3.76 170
Consolidated Net Income / (Loss)		 -20 -19 -18 -20 -20 -13 -25 2.52 -7.74 -3.76 170
Depreciation Expense		 0.37 0.36 0.36 0.36 0.34 0.33 0.33 0.01 0.01 0.01 0.01
Amortization Expense		 -0.66 -0.62 -0.55 -0.68 -0.98 -0.92 -0.72 -0.67 -0.54 -0.42 -0.35
Non-Cash Adjustments To Reconcile Net Income		 1.79 0.57 1.46 2.64 1.78 1.15 5.96 0.37 1.04 0.35 1.20
Changes in Operating Assets and Liabilities, net		 -3.18 1.71 -2.68 2.97 -2.16 1.66 5.57 -18 1.42 -0.86 -179
Net Cash From Investing Activities		 10 22 12 9.83 -12 13 11 16 -10 -1.36 2.20
Net Cash From Continuing Investing Activities		 10 22 12 9.83 -12 13 11 16 -10 -1.36 2.20
Purchase of Investments		 -7.09 -24 -25 -33 -40 -43 -35 -28 -51 -26 -14
Sale and/or Maturity of Investments		 18 46 37 42 28 57 46 44 41 24 16
Net Cash From Financing Activities		 1.68 3.81 24 24 1.78 1.42 2.78 0.45 0.84 1.64 12
Net Cash From Continuing Financing Activities		 1.68 3.81 24 24 1.78 1.42 2.78 0.45 0.84 1.64 12
Issuance of Common Equity		 1.68 3.81 22 22 0.19 -0.00 0.13 - 0.05 - 0.09
Other Financing Activities, net		 - 0.00 2.45 2.01 1.59 1.42 2.65 0.45 0.79 1.64 12
Effect of Exchange Rate Changes		 0.01 0.01 -0.01 -0.01 0.01 -0.03 0.00 0.02 -0.01 0.00 -0.01

Annual Balance Sheets for Arbutus Biopharma

This table presents Arbutus Biopharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 712 276 237 228 106 137 204 195 144 132 95
Total Current Assets		 184 133 129 129 94 128 161 151 132 127 94
Cash & Equivalents		 167 23 54 37 32 52 109 31 26 36 18
Short-Term Investments		 15 107 72 88 59 71 46 116 100 86 73
Accounts Receivable		 1.14 0.40 0.53 1.43 1.20 1.31 0.90 1.35 1.78 2.41 1.45
Prepaid Expenses		 1.20 1.31 2.14 3.18 1.79 3.12 4.45 2.87 4.25 2.28 1.54
Plant, Property, & Equipment, net		 3.18 6.95 12 10 8.68 6.93 5.98 5.07 4.67 3.31 0.03
Total Noncurrent Assets		 525 136 96 89 3.03 2.45 38 39 7.70 1.08 0.13
Other Noncurrent Operating Assets		 - - - 0.00 3.03 2.45 2.15 1.85 1.42 1.08 0.13
Total Liabilities & Shareholders' Equity		 712 276 237 228 106 137 204 195 144 132 95
Total Liabilities		 165 73 55 28 33 35 35 59 38 34 18
Total Current Liabilities		 11 11 15 11 7.83 9.54 11 33 22 16 6.01
Accounts Payable		 8.83 9.91 11 9.43 7.24 9.15 11 16 10 7.56 5.46
Other Current Liabilities		 0.88 0.11 0.00 1.33 0.34 0.39 0.38 0.37 0.43 0.48 0.55
Total Noncurrent Liabilities		 154 62 40 16 25 26 24 26 16 19 12
Other Noncurrent Operating Liabilities		 7.50 9.07 10 3.13 25 26 24 20 16 16 12
Total Equity & Noncontrolling Interests		 548 203 182 200 73 102 169 137 106 97 77
Total Preferred & Common Equity		 548 203 182 200 73 102 169 137 106 97 77
Total Common Equity		 548 203 182 200 73 102 169 137 106 97 77
Common Stock		 864 904 919 927 954 1,047 1,352 1,391 1,431 1,492 1,505
Retained Earnings		 -267 -653 -738 -805 -970 -1,046 -1,134 -1,204 -1,277 -1,347 -1,380
Accumulated Other Comprehensive Income / (Loss)		 -50 -48 -48 -48 -48 -48 -48 -50 -48 -48 -48

Quarterly Balance Sheets for Arbutus Biopharma

This table presents Arbutus Biopharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 204 191 177 159 150 160 140 117 103 98 277
Total Current Assets		 141 153 159 142 136 148 133 117 103 97 277
Cash & Equivalents		 24 41 27 18 43 63 32 37 37 22 24
Short-Term Investments		 111 106 125 117 86 79 96 76 61 71 72
Accounts Receivable		 1.84 2.66 2.61 2.17 2.14 1.77 1.61 1.18 1.03 0.91 180
Prepaid Expenses		 4.58 3.46 3.70 5.26 4.49 4.47 3.38 2.92 4.01 2.84 1.73
Plant, Property, & Equipment, net		 5.24 4.85 5.37 5.03 4.41 4.06 3.56 0.17 0.15 0.14 0.02
Total Noncurrent Assets		 57 34 13 12 10 7.76 4.11 0.03 0.00 0.13 0.13
Other Noncurrent Operating Assets		 1.99 1.73 1.60 1.51 1.33 1.24 1.14 0.03 0.00 0.13 0.13
Total Liabilities & Shareholders' Equity		 204 191 177 159 150 160 140 117 103 98 277
Total Liabilities		 58 47 42 39 36 38 34 38 20 20 17
Total Current Liabilities		 28 25 25 22 20 23 19 19 5.02 5.18 5.11
Accounts Payable		 12 9.65 8.81 9.81 8.25 11 7.54 12 4.51 4.65 4.47
Other Current Liabilities		 0.36 0.45 0.40 0.41 0.50 0.45 0.47 0.56 0.51 0.53 0.63
Total Noncurrent Liabilities		 31 22 18 17 15 15 15 18 15 15 12
Other Noncurrent Operating Liabilities		 20 19 18 17 15 15 15 16 15 15 12
Total Equity & Noncontrolling Interests		 146 144 135 119 115 122 107 79 83 77 260
Total Preferred & Common Equity		 146 144 135 119 115 122 107 79 83 77 260
Total Common Equity		 146 144 135 119 115 122 107 79 83 77 260
Common Stock		 1,378 1,414 1,421 1,426 1,458 1,485 1,489 1,498 1,500 1,502 1,519
Retained Earnings		 -1,182 -1,220 -1,237 -1,257 -1,295 -1,314 -1,334 -1,371 -1,369 -1,376 -1,210
Accumulated Other Comprehensive Income / (Loss)		 -51 -50 -49 -49 -48 -48 -48 -48 -48 -48 -48

Annual Metrics And Ratios for Arbutus Biopharma

This table displays calculated financial ratios and metrics derived from Arbutus Biopharma's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 54,569,791.00 54,841,494.00 55,051,995.00 55,477,235.00 56,850,172.00 84,909,258.00 135,269,247.00 - - - 192,324,017.00
DEI Adjusted Shares Outstanding		 54,569,791.00 54,841,494.00 55,051,995.00 55,477,235.00 56,850,172.00 84,909,258.00 135,269,247.00 - - - 192,324,017.00
DEI Earnings Per Adjusted Shares Outstanding		 -1.15 -7.01 -1.55 -1.21 -2.90 -0.89 -0.65 - - - -0.17
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -73 -344 -78 -63 -101 -40 -51 -46 -55 -53 -27
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -51.57% -54.87% -34.88%
Earnings before Interest and Taxes (EBIT)		 -80 -491 -110 -64 -144 -58 -74 -65 -78 -76 -37
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -79 -489 -108 -62 -142 -56 -71 -64 -79 -78 -39
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -453 -60 -61 -61 -29 -37 -51 -20 -76 -54 -37
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 356 72 56 53 -18 -21 -22 -47 -26 -25 -15
Increase / (Decrease) in Invested Capital		 380 -284 -16 -2.13 -71 -3.21 -0.26 -26 21 1.01 10
Book Value per Share		 $10.04 $3.70 $3.31 $3.61 $1.28 $1.20 $1.25 $0.87 $0.63 $0.51 $0.40
Tangible Book Value per Share		 $0.60 $1.44 $1.81 $2.41 $1.28 $1.20 $1.25 $0.87 $0.63 $0.51 $0.40
Total Capital		 548 215 194 200 73 102 169 137 106 97 77
Total Debt		 0.00 12 12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 12 12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -191 -131 -127 -147 -91 -123 -191 -184 -132 -123 -91
Capital Expenditures (CapEx)		 2.29 3.97 7.26 1.11 0.58 0.23 0.81 0.51 0.99 0.18 -0.36
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -8.00 -8.58 -12 -6.63 -4.83 -5.11 -5.88 -29 -16 -11 -3.02
Debt-free Net Working Capital (DFNWC)		 173 122 115 118 86 118 149 118 110 112 88
Net Working Capital (NWC)		 173 122 115 118 86 118 149 118 110 112 88
Net Nonoperating Expense (NNE)		 -10 40 6.76 -5.79 53 23 25 24 18 16 6.79
Net Nonoperating Obligations (NNO)		 -191 -131 -127 -147 -91 -123 -191 -184 -132 -123 -91
Total Depreciation and Amortization (D&A)		 0.59 1.09 2.03 2.18 2.30 2.19 2.75 1.37 -0.79 -1.76 -1.99
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.34) ($7.24) ($1.56) ($1.21) ($2.89) ($1.00) ($0.83) ($0.46) ($0.44) ($0.38) ($0.17)
Adjusted Weighted Average Basic Shares Outstanding		 45.46M 53.07M 54.72M 55.30M 68.94M 95.58M 106.24M 150.94M 165.96M 185.61M 191.60M
Adjusted Diluted Earnings per Share		 ($1.34) ($7.24) ($1.56) ($1.21) ($2.89) ($1.00) ($0.83) ($0.46) ($0.44) ($0.38) ($0.17)
Adjusted Weighted Average Diluted Shares Outstanding		 45.46M 53.07M 54.72M 55.30M 68.94M 95.58M 106.24M 150.94M 165.96M 185.61M 191.60M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($2.89) ($1.00) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 54.63M 55.02M 55.07M 56.12M 57.09M 75.84M 148.64M 162.57M 179.49M 191.48M 195.48M
Normalized Net Operating Profit after Tax (NOPAT)		 -39 -70 -49 -49 -50 -40 -50 -44 -55 -49 -19
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for Arbutus Biopharma

This table displays calculated financial ratios and metrics derived from Arbutus Biopharma's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - 191,480,188.00 191,527,129.00 191,698,695.00 192,324,017.00 195,478,068.00
DEI Adjusted Shares Outstanding		 - - - - - - 191,480,188.00 191,527,129.00 191,698,695.00 192,324,017.00 195,478,068.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - -0.13 0.01 -0.04 -0.02 0.87
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -21.74% -65.65% -77.09% -62.89% -71.25% -26.62% 15.14% 522.19% -60.49% - 10,054.54%
EBITDA Growth		 -24.31% 3.80% -12.11% -22.13% -1.10% 32.70% -33.25% 103.89% 58.33% - 746.22%
EBIT Growth		 -20.86% 5.30% -11.30% -21.65% 0.54% 34.64% -32.61% 106.99% 59.55% - 757.31%
NOPAT Growth		 -21.04% 8.04% -11.20% -17.39% 0.55% 32.84% -32.72% 109.85% 59.61% - 1,038.94%
Net Income Growth		 -14.44% 11.95% -9.40% -15.81% 1.93% 35.11% -37.21% 112.75% 60.73% - 791.90%
EPS Growth		 0.00% 7.69% 0.00% -10.00% 16.67% 41.67% -30.00% 109.09% 60.00% - 769.23%
Operating Cash Flow Growth		 -16.54% -1.78% 29.32% 25.84% 4.81% 40.35% 30.60% -8.58% 71.95% - 39.44%
Free Cash Flow Firm Growth		 -431.54% -454.49% 25.82% 43.24% 52.08% 69.83% 68.97% 47.15% 17.31% - -283.36%
Invested Capital Growth		 43.23% 44.61% 32.72% 9.67% 5.81% 3.85% -44.12% 42.01% 31.70% - 591.66%
Revenue Q/Q Growth		 0.15% -53.95% -28.58% 12.66% -22.42% 17.55% 12.07% 508.79% -95.07% - 16,943.39%
EBITDA Q/Q Growth		 -21.74% 0.97% 6.76% -11.94% -0.78% 34.08% -79.19% 103.27% -1,179.93% - 3,453.64%
EBIT Q/Q Growth		 -21.43% 0.85% 6.55% -11.43% 0.72% 34.84% -83.98% 105.87% -674.62% - 3,759.74%
NOPAT Q/Q Growth		 -17.26% 3.76% 6.67% -11.47% 0.66% 35.01% -84.45% 108.27% -507.35% - 4,661.38%
Net Income Q/Q Growth		 -17.61% 3.94% 7.44% -10.75% 0.40% 36.44% -95.71% 110.29% -406.86% - 4,617.97%
EPS Q/Q Growth		 -20.00% 0.00% 16.67% -10.00% 9.09% 30.00% -85.71% 107.69% -500.00% - 8,800.00%
Operating Cash Flow Q/Q Growth		 -11.38% 20.62% -11.58% 24.83% -42.97% 50.26% -29.82% -17.61% 63.06% - -73.29%
Free Cash Flow Firm Q/Q Growth		 -9.07% -3.75% 30.27% 28.06% 7.92% 34.67% 28.29% -22.54% -44.06% - -110.40%
Invested Capital Q/Q Growth		 12.16% -3.67% 11.38% -11.94% 8.41% -5.82% -32.83% 54.96% -7.88% - 1,207.43%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
EBITDA Margin		 -468.89% -1,008.35% -1,277.68% -1,269.47% -1,649.14% -924.78% -1,478.63% 7.93% -1,739.32% - 94.10%
Operating Margin		 -462.82% -967.23% -1,263.90% -1,250.46% -1,601.19% -885.20% -1,456.86% 13.86% -1,636.86% - 94.30%
EBIT Margin		 -462.69% -996.22% -1,264.75% -1,250.93% -1,600.82% -887.29% -1,456.63% 14.05% -1,639.13% - 94.29%
Profit (Net Income) Margin		 -431.60% -900.33% -1,166.78% -1,146.93% -1,472.52% -796.19% -1,390.36% 23.49% -1,463.52% - 94.74%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Interest Burden Percent		 93.28% 90.37% 92.25% 91.69% 91.99% 89.73% 95.45% 167.20% 89.29% - 100.47%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 274.77%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 274.01%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - -167.91%
Return on Equity (ROE)		 -56.99% -59.99% -57.54% -59.96% -67.81% -68.76% -79.02% -52.82% -45.88% - 106.86%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - -25.49%
Operating Return on Assets (OROA)		 -56.79% -106.37% -96.18% -74.72% -72.17% -39.66% -69.79% 1.65% -201.06% - 91.59%
Return on Assets (ROA)		 -52.97% -96.13% -88.73% -68.51% -66.39% -35.59% -66.61% 2.75% -179.52% - 92.02%
Return on Common Equity (ROCE)		 -56.99% -59.99% -57.54% -59.96% -67.81% -68.76% -79.02% -52.82% -45.88% - 106.86%
Return on Equity Simple (ROE_SIMPLE)		 -63.24% 0.00% -64.89% -62.95% -71.76% 0.00% -96.73% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -15 -15 -14 -15 -15 -9.75 -18 1.49 -6.06 -3.70 169
NOPAT Margin		 -323.97% -677.06% -884.73% -875.32% -1,120.84% -619.64% -1,019.80% 13.86% -1,145.80% - 94.30%
Net Nonoperating Expense Percent (NNEP)		 -2.99% -3.03% -2.73% -3.00% -3.42% -2.18% -5.22% 0.84% -1.50% - 0.76%
Return On Investment Capital (ROIC_SIMPLE)		 - -13.70% - - - -10.02% -22.73% 1.79% -7.83% -4.84% 64.92%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
SG&A Expenses to Revenue		 125.42% 237.81% 346.74% 437.25% 338.84% 299.36% 330.61% 30.99% 575.43% - 3.29%
R&D to Revenue		 433.00% 818.83% 1,005.42% 900.98% 1,065.94% 559.72% 507.88% 51.20% 1,092.25% - 2.30%
Operating Expenses to Revenue		 562.82% 1,037.58% 1,363.90% 1,350.46% 1,701.19% 985.20% 1,556.86% 86.14% 1,736.86% - 5.70%
Earnings before Interest and Taxes (EBIT)		 -22 -21 -19 -22 -21 -14 -26 1.51 -8.67 -4.62 169
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -22 -22 -20 -22 -22 -15 -26 0.85 -9.20 -5.03 169
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.85 3.95 4.04 4.76 6.80 6.36 8.44 7.13 11.24 - 3.38
Price to Tangible Book Value (P/TBV)		 2.85 3.95 4.04 4.76 6.80 6.36 8.44 7.13 11.24 - 3.38
Price to Revenue (P/Rev)		 15.29 23.11 35.66 57.96 107.80 100.41 104.37 38.39 59.59 - 4.59
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 5.47
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 18.27%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 4.76
Enterprise Value to Revenue (EV/Rev)		 8.79 15.82 25.04 43.20 88.41 80.54 86.77 32.03 53.17 - 4.10
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 5.06
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 4.99
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 5.01
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Financial Leverage		 -1.26 -1.30 -1.22 -1.21 -1.22 -1.25 -1.29 -1.20 -1.22 - -0.61
Leverage Ratio		 1.37 1.40 1.32 1.31 1.32 1.36 1.38 1.28 1.29 - 1.16
Compound Leverage Factor		 1.28 1.26 1.22 1.20 1.22 1.22 1.32 2.14 1.15 - 1.17
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Altman Z-Score		 -5.31 -5.28 -3.68 -1.63 0.22 -2.77 -5.48 0.28 6.98 - 28.84
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.34 5.87 6.69 6.56 7.02 8.15 6.01 20.53 18.80 - 54.26
Quick Ratio		 6.11 5.68 6.47 6.36 6.84 8.01 5.86 19.74 18.25 - 53.92
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -34 -36 -25 -18 -16 -11 -7.72 -9.46 -14 -14 -30
Operating Cash Flow to CapEx		 -68,075.00% 0.00% -20,310.53% -1,450,400.00% 0.00% -11,994.19% 0.00% 0.00% 0.00% - 0.00%
Free Cash Flow to Firm to Interest Expense		 -747.58 -810.86 -565.39 -526.39 -568.24 -358.84 -275.69 -337.82 -592.45 - -1,740.76
Operating Cash Flow to Interest Expense		 -473.57 -393.00 -438.52 -426.59 -715.03 -343.83 -478.25 -562.46 -252.91 - -477.06
Operating Cash Flow Less CapEx to Interest Expense		 -474.26 -393.00 -440.68 -426.62 -715.03 -346.70 -478.25 -562.46 -252.91 - -477.06
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.12 0.11 0.08 0.06 0.05 0.04 0.05 0.12 0.12 - 0.97
Accounts Receivable Turnover		 11.10 11.60 5.41 4.59 3.57 2.95 3.86 11.04 11.62 - 2.11
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Fixed Asset Turnover		 4.33 3.72 2.80 2.13 1.57 1.55 2.79 7.33 7.91 - 2,015.21
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Sales Outstanding (DSO)		 32.87 31.47 67.50 79.47 102.29 123.77 94.66 33.05 31.40 - 172.77
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Cash Conversion Cycle (CCC)		 32.87 31.47 67.50 79.47 102.29 123.77 94.66 33.05 31.40 - 172.77
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -25 -26 -23 -26 -24 -25 -34 -15 -16 -15 165
Invested Capital Turnover		 -0.64 -0.49 -0.45 -0.37 -0.27 -0.24 -0.23 -0.75 -0.73 - 2.91
Increase / (Decrease) in Invested Capital		 19 21 11 2.79 1.47 1.01 -10 11 7.57 10 199
Enterprise Value (EV)		 195 287 325 435 596 497 556 494 777 - 784
Market Capitalization		 340 419 463 583 727 620 668 592 870 - 880
Book Value per Share		 $0.71 $0.63 $0.64 $0.65 $0.57 $0.51 $0.41 $0.43 $0.40 $0.40 $1.33
Tangible Book Value per Share		 $0.71 $0.63 $0.64 $0.65 $0.57 $0.51 $0.41 $0.43 $0.40 $0.40 $1.33
Total Capital		 119 106 115 122 107 97 79 83 77 77 260
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -145 -132 -138 -149 -131 -123 -113 -98 -94 -91 -95
Capital Expenditures (CapEx)		 0.03 0.00 0.10 0.00 0.00 0.09 0.00 0.00 0.00 -0.36 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -15 -16 -14 -16 -14 -11 -15 0.01 -1.44 -3.02 177
Debt-free Net Working Capital (DFNWC)		 119 110 116 126 114 112 97 98 92 88 272
Net Working Capital (NWC)		 119 110 116 126 114 112 97 98 92 88 272
Net Nonoperating Expense (NNE)		 5.01 4.79 4.32 4.69 4.71 2.78 6.54 -1.04 1.68 0.05 -0.79
Net Nonoperating Obligations (NNO)		 -145 -132 -138 -149 -131 -123 -113 -98 -94 -91 -95
Total Depreciation and Amortization (D&A)		 -0.29 -0.26 -0.20 -0.32 -0.65 -0.59 -0.39 -0.66 -0.53 -0.41 -0.34
Debt-free, Cash-free Net Working Capital to Revenue		 -66.98% -90.75% -105.22% -162.62% -206.76% -177.04% -239.42% 0.06% -9.89% - 92.29%
Debt-free Net Working Capital to Revenue		 536.32% 603.83% 890.00% 1,248.63% 1,688.73% 1,810.05% 1,520.80% 636.33% 631.64% - 142.03%
Net Working Capital to Revenue		 536.32% 603.83% 890.00% 1,248.63% 1,688.73% 1,810.05% 1,520.80% 636.33% 631.64% - 142.03%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.12) ($0.12) ($0.10) ($0.11) ($0.10) ($0.07) ($0.13) $0.01 ($0.04) ($0.01) $0.88
Adjusted Weighted Average Basic Shares Outstanding		 167.51M 165.96M 175.63M 188.04M 189.00M 185.61M 190.71M 191.55M 191.78M 191.60M 193.77M
Adjusted Diluted Earnings per Share		 ($0.12) ($0.12) ($0.10) ($0.11) ($0.10) ($0.07) ($0.13) $0.01 ($0.04) ($0.01) $0.87
Adjusted Weighted Average Diluted Shares Outstanding		 167.51M 165.96M 175.63M 188.04M 189.00M 185.61M 190.71M 192.40M 191.78M 191.60M 195.21M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 167.70M 179.49M 188.72M 188.78M 189.49M 191.48M 191.53M 191.70M 192.32M 195.48M 197.54M
Normalized Net Operating Profit after Tax (NOPAT)		 -15 -15 -14 -15 -12 -9.75 -9.33 1.16 -5.99 -3.49 118
Normalized NOPAT Margin		 -323.97% -677.06% -884.73% -875.32% -931.33% -619.64% -528.81% 10.77% -1,132.84% - 66.01%
Pre Tax Income Margin		 -431.60% -900.33% -1,166.78% -1,146.93% -1,472.52% -796.19% -1,390.36% 23.49% -1,463.52% - 94.74%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -468.52 -485.66 -440.36 -635.03 -739.14 -465.53 -917.68 53.89 -377.00 - 9,935.12
NOPAT to Interest Expense		 -328.06 -330.07 -308.05 -444.36 -517.52 -325.10 -642.48 53.14 -263.53 - 9,935.76
EBIT Less CapEx to Interest Expense		 -469.22 -485.66 -442.52 -635.06 -739.14 -468.40 -917.68 53.89 -377.00 - 9,935.12
NOPAT Less CapEx to Interest Expense		 -328.75 -330.07 -310.21 -444.39 -517.52 -327.97 -642.48 53.14 -263.53 - 9,935.76
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%

Financials Breakdown Chart

Key Financial Trends

Arbutus Biopharma (ABUS) has shown a pattern of uneven quarterly results across the last four years, with revenue volatility, frequent equity financing, and persistent cash burn, but also notable cash inflows from investment activity in several quarters. Here are the most relevant, data-backed observations for retail investors.

  • Q2 2025 net income from continuing operations was positive: $2.52 million, marking a rare quarterly positive result within the period analyzed.
  • Q2 2025 operating revenue reached $10.74 million, the strongest quarterly revenue in the period covered.
  • Q4 2025 cash inflow from sale/maturity of investments was $23.83 million, contributing meaningful liquidity in that quarter.
  • Q2 2025 cash flow from continuing financing activities was +$24.37 million, providing a notable liquidity lift from financing activities.
  • Balance sheet liquidity signals in 2025: total assets around $103.3 million and total equity around $83 million, suggesting a positive equity cushion despite ongoing losses.
  • Revenue is highly volatile across quarters, with spikes in some periods (e.g., Q2 2025) and much lower levels in others, indicating a lack of steady top-line growth.
  • Equity financing is a recurring theme (issuances of common stock in multiple quarters), which can dilute shares and reflect ongoing fundraising needs.
  • Cash and investments mix fluctuates, with sizable shifts between cash, short-term investments, and sale/maturity proceeds, implying ongoing liquidity management.
  • Chronic net losses recur across quarters, including Q4 2025 consolidated net income of -$3.76 million and similar patterns in prior years.
  • Operating cash flow is negative in most quarters, evidencing ongoing cash burn (for example, Q3 2025 CFO around -$5.82 million; Q4 2025 CFO around -$4.68 million).
05/15/26 10:12 PM ETAI Generated. May Contain Errors.

Arbutus Biopharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Arbutus Biopharma's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Arbutus Biopharma's net income appears to be on a downward trend, with a most recent value of -$33.50 million in 2025, falling from -$62.72 million in 2015. The previous period was -$69.92 million in 2024. View Arbutus Biopharma's forecast to see where analysts expect Arbutus Biopharma to go next.

Arbutus Biopharma's total operating income in 2025 was -$38.16 million, based on the following breakdown:
  • Total Gross Profit: $14.08 million
  • Total Operating Expenses: $52.24 million

Over the last 10 years, Arbutus Biopharma's total revenue changed from $23.28 million in 2015 to $14.08 million in 2025, a change of -39.5%.

Arbutus Biopharma's total liabilities were at $18.04 million at the end of 2025, a 47.5% decrease from 2024, and a 89.0% decrease since 2015.

In the past 10 years, Arbutus Biopharma's cash and equivalents has ranged from $18.01 million in 2025 to $166.78 million in 2015, and is currently $18.01 million as of their latest financial filing in 2025.

Over the last 10 years, Arbutus Biopharma's book value per share changed from 10.04 in 2015 to 0.40 in 2025, a change of -96.0%.


Related Companies

Financial statements for NASDAQ:ABUS last updated on 5/14/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel